Novartis and Boehringer Ingelheim are the latest pharma groups to launch DTC platforms offering cut-price medicines to US ...

In the past, it was easier for pharma to think of launch readiness as a checklist: secure NICE approval, mobilise commercial ...

LSX World Congress is a meeting place for biotechs, big pharma companies, and investors. Milenko Cicmil is familiar with all three worlds as CEO of Tasca Therapeutics, an investor with Cure Ventures, ...

At this year’s LSX World Congress in Boston, an entire track was devoted to Obesity Science and Innovation, with pharma ...

Already a blockbuster therapy for advanced breast cancer and other indications like gastric cancer, Enhertu made revenues of ...

Investors were spooked by the miss, and shares in Nasdaq-listed Enanta were down around 11%, having risen sharply in ...

AstraZeneca is the latest big pharma group to open up a Direct-To-Consumer (DTC) sales channel in the US, offering three of ...

Antibody specialist Genmab has continued its shift from out-licensing drugs to developing its own medicines with a deal to ...

Sarno discusses her favourite memory from Frontiers Health, as well as the importance of equity and accessibility for ...

Walmsley will step down from the board of directors of GSK at the end of the year, and will step down as CEO on 30th ...

A big part of Biogen's efforts to defend its spinal muscular atrophy (SMA) business has been dealt a setback by the FDA, which declined to approve a high-dose version of its flagship Spinraza product.

MSD has moved a step closer to completing its acquisition of Verona Pharma, after a vote in favour of the transaction by the UK company's shareholders. Investors in Verona – a specialist in ...